Digg icon reddit icon Stumbleupon icon
Print Email     Print Edition Stories

Tuesday, April 22, 2008

GlaxoSmithKline to buy Sirtris for $720M

British drug giant GlaxoSmithKline PLC has agreed to acquire Sirtris Pharmaceuticals Inc. of Cambridge for $720 million.

Glaxo said it would keep Sirtris (NASDAQ: SIRT) as an autonomous unit of its drug discovery business and plans to retain Sirtris CEO Christoph Westphal and the rest of the company's employees. The British pharmaceutical firm (NYSE: GSK) plans to begin a tender offer of $22.50 per share of Sirtris common stock in May and close the deal in the second quarter of 2007. Sirtris's stock closed at $12.23 per share Tuesday.

Sirtris has gained wide recognition for its experimental, anti-aging treatments. The firm has a pipeline of small-molecule drugs that target genes linked to enzymes called sirtuins that are believe to have anti-aging effects and could be used to treat diabetes, cancer and other major diseases.

With 57 employees, the biotech firm reported a 2007 net loss of $31.1 million and no revenue. Glaxo said it would maintain Sirtris' operations in Cambridge.

Digg icon reddit icon Stumbleupon icon
Contact Editor Latest News

Comments

Please Login/Register to post comments.

No comments have been added or approved.

On the MHT blog now

Women’s wisdom comes back around

By Michelle Lang If you’ve ever heard the lyrics to Brad Paisley’s “Letter to Me”, you know that the country crooner made a song of taking his adult wisdom and imparting it on his 17-year-old self, reminding him not to bother arguing with his dad, to enjoy the adventure of his date with Bridget, and to thank his teacher for spending time with him. The same concept is done daily by pa...

Read More

Most Popular Stories
EmailedViewed
Stay Informed
Check which newsletter you'd like to receive.
TechFlash (Daily)
FinanceFlash (Daily)
BioFlash (Daily)
GreenFlash (Weekly)
Startup Report (Weekly)
Breaking news, MHT events, local announcements
RSS feeds
Your email:

Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com

Web Site Developed by Neptune Web, Inc.

Use of, registration on, this site constitutes acceptance of our User Agreement. Please read our Privacy Policy (updated) A publishing partner with Portfolio